These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 21735833)

  • 21. Pegylated alpha-interferon-2a plus ribavirin compared with pegylated alpha-interferon-2b plus ribavirin for initial treatment of chronic hepatitis C virus: prospective, non-randomized study.
    Escudero A; Rodríguez F; Serra MA; Del Olmo JA; Montes F; Rodrigo JM
    J Gastroenterol Hepatol; 2008 Jun; 23(6):861-6. PubMed ID: 18422960
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predictive value of early virological response to treatment with different interferon-based regimens plus ribavirin in patients with chronic hepatitis C.
    Napoli N; Giannelli G; Parisi CV; Antonaci A; Maddalena G; Antonaci S
    New Microbiol; 2005 Jan; 28(1):13-21. PubMed ID: 15782622
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chronic hepatitis C virus genotype 6 infection: response to pegylated interferon and ribavirin.
    Fung J; Lai CL; Hung I; Young J; Cheng C; Wong D; Yuen MF
    J Infect Dis; 2008 Sep; 198(6):808-12. PubMed ID: 18657036
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C.
    Martin-Carbonero L; Nuñez M; Mariño A; Alcocer F; Bonet L; García-Samaniego J; López-Serrano P; Cordero M; Portu J; Soriano V
    AIDS; 2008 Jan; 22(1):15-21. PubMed ID: 18090387
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment failure with new hepatitis C drugs.
    Soriano V; Vispo E; Poveda E; Labarga P; Barreiro P
    Expert Opin Pharmacother; 2012 Feb; 13(3):313-23. PubMed ID: 22242928
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antiviral activity of narlaprevir combined with ritonavir and pegylated interferon in chronic hepatitis C patients.
    de Bruijne J; Bergmann JF; Reesink HW; Weegink CJ; Molenkamp R; Schinkel J; Tong X; Li J; Treitel MA; Hughes EA; van Lier JJ; van Vliet AA; Janssen HL; de Knegt RJ
    Hepatology; 2010 Nov; 52(5):1590-9. PubMed ID: 20938912
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Treatment of hepatitis C: current status and perspectives].
    Pol S; Corouge M
    Rev Prat; 2014 May; 64(5):605-12. PubMed ID: 24923038
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase III results of Boceprevir in treatment naïve patients with chronic hepatitis C genotype 1.
    Manns MP; Markova AA; Calle Serrano B; Cornberg M
    Liver Int; 2012 Feb; 32 Suppl 1():27-31. PubMed ID: 22212568
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Optimal treatment with telaprevir for chronic HCV infection.
    Jesudian AB; Jacobson IM
    Liver Int; 2013 Feb; 33 Suppl 1():3-13. PubMed ID: 23286840
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A simple rule to personalize standard dual therapy across all genotypes in naive chronic hepatitis C patients: the TT4 randomized trial.
    Francioso S; Almerighi C; Forte P; Bandiera F; Nosotti L; Lionetti R; Taliani G; Piras MR; Ponti ML; Parruti G; Di Candilo F; Gentile S; Piccolo P; Salso A; Riccobelli F; Renzi S; Longo MA; Montalbano M; Zaru S; Biliotti E; Di Masi F; Santopaolo F; Angelico M
    Dig Liver Dis; 2014 Feb; 46(2):164-9. PubMed ID: 24239044
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Induction pegylated interferon alfa-2b in combination with ribavirin in patients with genotypes 1 and 4 chronic hepatitis C: a prospective, randomized, multicenter, open-label study.
    Brady DE; Torres DM; An JW; Ward JA; Lawitz E; Harrison SA
    Clin Gastroenterol Hepatol; 2010 Jan; 8(1):66-71.e1. PubMed ID: 19747986
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of aging, glucose level, and HIV viral load on response to treatment with pegylated interferon plus ribavirin in HIV/HCV co-infected women.
    Nasta P; Maida I; Cattelan AM; Pontali E; Angeli E; Giralda M; Verucchi G; Caputo A; Iannacone C; Puoti M; Carosi G
    J Womens Health (Larchmt); 2015 Feb; 24(2):159-64. PubMed ID: 25682817
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of pegylated interferon and ribavirin for retreatment of chronic HCV infection in HIV co-infected patients failing a previous standard interferon-based regimen.
    Crespo M; Mira JA; Pineda JA; Van den Eynde E; Ríos-Villegas MJ; Collado A; Girón-González JA; López-Cortés LF; González-Serrano M; Rivero A; Merino D; Esteban JI
    J Antimicrob Chemother; 2008 Oct; 62(4):793-6. PubMed ID: 18567911
    [TBL] [Abstract][Full Text] [Related]  

  • 34. RG7128 alone or in combination with pegylated interferon-α2a and ribavirin prevents hepatitis C virus (HCV) Replication and selection of resistant variants in HCV-infected patients.
    Le Pogam S; Seshaadri A; Ewing A; Kang H; Kosaka A; Yan JM; Berrey M; Symonds B; De La Rosa A; Cammack N; Nájera I
    J Infect Dis; 2010 Nov; 202(10):1510-9. PubMed ID: 20942646
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hepatitis C virus directly acting antivirals: current developments with NS3/4A HCV serine protease inhibitors.
    Naggie S; Patel K; McHutchison J
    J Antimicrob Chemother; 2010 Oct; 65(10):2063-9. PubMed ID: 20688770
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interferon-based therapy for chronic hepatitis C: current and future perspectives.
    Zeuzem S
    Nat Clin Pract Gastroenterol Hepatol; 2008 Nov; 5(11):610-22. PubMed ID: 18838975
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Short duration treatment in genotype 1 chronic hepatitis C patients with rapid virologic response to pegylated interferon plus ribavirin.
    Bonardi R; Tabone M; Manca A; Pellicano R; Ciancio A; Rizzetto M
    Biomed Pharmacother; 2011 Jul; 65(4):303-6. PubMed ID: 21723079
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of interferon plus ribavirin in the treatment of hepatitis C virus genotype 5.
    Antaki N; Hermes A; Hadad M; Ftayeh M; Antaki F; Abdo N; Kebbewar K
    J Viral Hepat; 2008 May; 15(5):383-6. PubMed ID: 18086180
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fluvastatin as an adjuvant to pegylated interferon and ribavirin in HIV/hepatitis C virus genotype 1 co-infected patients: an open-label randomized controlled study.
    Milazzo L; Caramma I; Mazzali C; Cesari M; Olivetti M; Galli M; Antinori S
    J Antimicrob Chemother; 2010 Apr; 65(4):735-40. PubMed ID: 20118492
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rapid virological response in peripheral blood mononuclear cells with an increase of hepatitis C virus-specific interferon-gamma production predisposes to sustained virological response in patients with chronic hepatitis C genotype 1 undergoing treatment with pegylated-interferon alpha 2a plus ribavirin.
    Perrella A; Sbreglia C; Atripaldi L; Esposito C; D'Antonio A; Perrella O
    Scand J Gastroenterol; 2010; 45(2):250-5. PubMed ID: 19968615
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.